Navigation Links
Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
Date:3/15/2010

FREMONT, Calif., March 15 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Pink Sheets: VRML) today announced that due to the positive response to the national launch of its OVA1™ test this past week, the company's leadership will be attending the Society of Gynecologic Oncologists' (SGO) 41st Annual Meeting on Women's Cancer in San Francisco rather than presenting at the Roth 22nd Annual OC Growth Stock Conference in Laguna Niguel.

“The news surrounding our launch of OVA1™ last week and the announcement of the favorable Medicare coverage decision has placed increased demands on our time at the SGO meeting,” said Gail S. Page, Vermillion’s Chief Executive Officer.  “The physicians attending this meeting are at the forefront of ovarian cancer treatment and therefore we believe it should be our priority to provide them with further details on the OVA1 test.”

OVA1 is the first blood test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the pre-surgical evaluation of a woman's ovarian mass for cancer and is nationally available through Quest Diagnostics ( DGX).

About the OVA1 Test

The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers -- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

Forward Looking Statement:

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. There are no guarantees that Vermillion will succeed in its efforts to commercialize ovarian cancer or OVA1™ diagnostics products in 2010 or during any other period of time. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermillion; (2) unproven ability of Vermillion to develop, and commercialize diagnostic products based on findings from its disease association studies; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of market acceptance of its OVA1™ diagnostic test or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payers such as private insurance companies; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid or Vermillion's ability to relist its shares on the NASDAQ Global Market or on other national securities exchange; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

OVA1™ is a trademark of Vermillion, Inc.

SOURCE Vermillion, Inc.

Back to top

RELATED LINKS
http://www.vermillion.com

'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
2. Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
3. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
4. Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
5. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
6. Vermillion Announces Receipt of NASDAQ Panel Decision
7. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
8. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
9. Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
10. Vermillion Announces First Quarter 2008 Financial Results and Business Progress
11. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016   ... a biopharmaceutical company focused on the development and commercialization of ... the 18 th Annual BIO CEO & Investor ... EST in New York, NY . ... provide an update on the ongoing clinical trial of ...
(Date:2/4/2016)... Md. , Feb. 4, 2016  Spherix Incorporated ... to the fostering and monetization of intellectual property, today ... and Uniden in the Northern District of ... moving forward.  Inter Partes Re-examination ... U.S. Patent Office.  The IPR was initiated on only ...
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
(Date:2/3/2016)... 2016  Discovery Laboratories, Inc. (NASDAQ: DSCO ... KL4 surfactant therapies for respiratory diseases, today announced ... inducement award as a component of employment compensation ... President and Chief Executive Officer.  The award was ... 1, 2016 and granted as an inducement material ...
Breaking Biology Technology:
(Date:1/15/2016)... JUAN, Puerto Rico , Jan. 15, 2016 /PRNewswire/ ... companies big and small to find new ways to ... driven culture. iOS and Android ... device based on biometrics, transforming it into a hardware ... request that users swipe their fingerprint on their KodeKey ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the ... nearly 10,000 retail locations, web and mobile, today ... $40 million from existing investors. ... be devoted to further innovate higi,s health platform ... and web portal – including expanding services and ...
Breaking Biology News(10 mins):